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Abstract
The structure and dynamics of protein signalling networks governs cell decision processes
and the formation of tissue boundaries. Complex diseases such as cancer and diabetes
are diseases of such networks. Therefore approaches that can give insight into how these
networks change during disease progression are crucial for better understanding, detection
and intervention. The era of network medicine has begun; however, there are fundamental
principles associated with molecular networks that are essential to consider for this ﬁeld to
succeed. Here, we introduce network biology and some of its associated technologies. We
then focus on the multivariate nature of cellular networks and how this has implications for
biomarker and drug discovery using cancer metastasis as an example.
Copyright  2009 Pathological Society of Great Britain and Ireland. Published by John
Wiley & Sons, Ltd.
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Introduction
Molecular, phenotypic and patient tracing of disease
initiation and progression before, during and after ther-
apeutic intervention is paramount for the successful
treatment of (complex) diseases [1]. In the pursuit of
personalized medicine, this puts even more demand
on the ﬁne-tuned monitoring of molecular entities that
can give insight into the speciﬁc state of a diseased
patient or tumour. Traditionally, molecular pathology
has been performed by analysing well-characterized
individual genes, proteins or other molecules iden-
tiﬁed by targeted studies. Subsequently, this was
expanded to systematic interrogation of mRNA levels
using gene expression microarrays. This technology
has since been upgraded with full-genome, deep- and
transcriptome-sequencing platforms that, for example,
enables mRNA or non-coding RNA absolute quanti-
tation, detection of gene copy-numbers and genomic
sequencing [2]. Similarly, recent advances in mass
spectrometry-based analysis now enable detection and
quantitation of selected small compounds, proteins and
other biomolecules [3]. As a consequence, much hope
has been placed in so-called ‘biomarker discovery’,
which aims to identify and assess individual molec-
ular entities (proteins, in particular) to drive molecu-
lar pathology towards higher-throughput and clinical
applications, using technologies such as serum mass-
spectrometry. However, these efforts make assump-
tions that might conﬂict with our current under-
standing of how molecular networks and systems
become disease driving. Cellular signalling networks
are highly dynamic, in both structure and utilization
[4] and in both cell- and tissue-speciﬁc contexts [5,6]
(Figure 1).
In this review we discuss important aspects of
molecular networks that should be considered in the
design of biomarker assays. An essential aspect of cel-
lular signalling networks is that at any given time
they are in a given state that impacts directly on
the cellular response to an environmental stimula-
tion (or cue) [4–8]. This multivariate nature enables
cells to respond to multiple input cues in an inte-
grative and quantitative manner [7] (Figure 2). We
will argue that failing to describe network states
and biological context for molecular biomarkers
can have potentially damaging consequences for the
patient.
The cue, signal and response model of cell
signalling
Any given cell in a physiological (or non-physio-
logical) environment receives numerous simultane-
ous input cues that must be processed and inte-
grated to determine changes in cellular behaviour,
such as migration, proliferation, apoptosis and dif-
ferentiation [4,7] (Figure 1). Reversible protein mod-
iﬁcations are one of the underlying mechanisms for
cellular information processing in signalling networks
(Figure 2). Protein phosphorylation in particular has
proved to be a key media for cellular signal propa-
gation. Through the ability to control protein–protein
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Figure 1. Cue, signal and response model of cell behaviour. Cell behaviour is governed by multivariate network states. To process
multiple cues from the environment and/or internal changes, cells integrate information in signalling networks in order to respond
to these constantly varying inputs. Thus, to describe and construct predictive models of cell behaviour, quantitative measurements
of these network states and simultaneous quantitation of phenotype and multiple cues are essential
Figure 2. Control hierarchies important for phenotype and disease. The control networks that directly modulate or deﬁne
phenotype and cell/tissue behaviour are dynamic protein operations, in particular signalling networks. This cellular network layer
is in constant change and ﬂux, due to integration of inputs from other cellular control layers, eg, changes to the genome, mRNA
expressions or environmental cues. It is the interplay of these integrative cellular information-processing systems that can converge
towards diseased states and ultimately can initiate and drive complex regulatory disease such as cancer
interactions, protein–phospholipid interactions, struc-
tural complex nucleation, allosteric structural reorga-
nization, enzyme activity and degradation and translo-
cation, phosphorylation impacts on every aspect of
cellular biology [4,9]. Cell behaviour and pheno-
type are directly controlled by dynamic networks of
protein interactions in response to external or inter-
nal cues/stimuli (Figures 1, 2). Signalling networks,
such as those regulated by kinases and phospho-
binding domains (eg the SH2 domains) are essen-
tial for the integrative response a cell must make at
any given point in time to extra- or intracellular cues
[4–11].
Integrative network biology
While studying molecular interactions has been a
research focus for many years and has provided much
insight into biology, the new age has come for inte-
grative network biology. The aim with integrative net-
work biology is to provide models of cellular networks
based on integration of a large and heterogeneous
dataset, eg originating from proteomics and high-
throughput functional genomics studies [4,10–14].
We, and others, have shown that the network mod-
els pertaining to cellular signalling can also be uti-
lized for ﬁne-grained prediction of human disease
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[15–18]. Through quantitative systematic measure-
ments of these networks and integration of multiple
types of data, it is now possible to deﬁne dynamic
changes to these networks and perform computational
modelling of the networks that enables predictions
to be made about speciﬁc responses such systems
should elicit [4,7,8,13]. In particular, we have recently
shown that, integrating systems genetics data [19] with
phospho-proteomics data and computational models of
cellular kinase speciﬁcity [11], we could derive an
integrative network model of JNK regulation in the
fruit ﬂy [12]. This network can now serve as a frame-
work for future targeted proteomics studies [20,21] in
cancer cells (in vitro and in vivo) to deﬁne how the
network evolves and changes during cancer progres-
sion. We are now actively pursuing the integration of
data from deep sequencing, functional genomics and
extreme-throughput microscopy and mass spectrom-
etry to perform network medicine and systems-level
modelling of cancer metastasis [4,18].
A potential concern with systems-level data and
derived models relates to the fact that these datasets
most often are incomplete and often associated with
signiﬁcant errors. There are numerous ways to address
this; here we will simply make the point that one
advantage of integrating data from different sources
is that the amount of false-positive observations will
be reduced, as the independent observations from the
various data sources contribute to the overall proba-
bility of a network edge (or similar) being true. At the
modelling level these issues must always be dealt with
in two independent ways: ﬁrst, any model should be
experimentally validated and predictive of phenotype
or cellular behaviour; second, a computational model
should always be ‘benchmarked’ through ‘in silico’
validation. The latter requires golden datasets and is
not always possible, but both approaches can signiﬁ-
cantly enhance the power of a model [10]. A related
issue is that of so-called ‘biological noise’: eg not all
phosphorylation events or protein–protein interactions
in a cell necessarily result in phenotypic change [19];
thus, how does integrative network biology assist in
analysing such events? As above, the integration of,
for example, systems genetic data with physical inter-
action data will very likely unravel such cases, as
likely only one type of association will be observed.
However, many such interactions might actually have
a function although they do not lead to an ‘observ-
able’ cellular or higher phenotype, and we stress that
one needs to be careful about excluding data based
on hypothetical noise models. Finally, because inte-
gration of data relies on quantitative measurements, it
is key that samples (such as a proteomics samples) are
analysed in biological and technical triplicates.
Multivariate nature of cellular networks
A fundamental and essential aspect to cellular net-
works is that they are multivariate (Figure 1). As cells
must be able to receive and respond to many hun-
dreds or even thousands of concurrent external and
internal cues, these are processed by signalling net-
works in an integrative fashion. In other words, the
cell in a sense computes its response by taking into
account not one but many inputs, and in particular
it takes into account the current state of its signalling
networks. This aspect of cell signalling (and biological
networks) was shown in a seminal paper from the lab-
oratories of Lauffenburger and Yaffe [7]. This paper
showed that while the activating phosphorylation of
JNK kinase had been previously debated to be either
anti- or pro-apoptotic, it can indeed be both, as this
entirely depends on the state of the network when it
receives either a TNF or EGF cue. A systems model
for JNK signalling was established and it was shown
that the model provided stronger predictive power
when the multivariate analysis was used as founda-
tion. In a similar study, the MIT labs showed how
common information processing mediates cell-speciﬁc
responses to stimuli [5]. Therefore, to fully under-
stand a cellular response to a perturbation (such as
to a drug), it is essential to analyse this in the context
of the cell’s multivariate state [5–7]. This observation
does not just have implications for biomarker discov-
ery, as discussed below, but also for how analysis of
biological systems should be performed. For example,
whereas treating a cell line with a ligand and perform-
ing global phospho-proteomics might be informative,
it is intrinsically a single-dimensional approach that
ignores the multivariate nature of the system under
study. A titration study where both ligand and recep-
tor are utilized would not only be more informative
but also would enable predictive models to be created.
The multivariate nature of cellular networks is also
important for genetic studies; whereas the knockdown
or deletion of a single gene can provide insight into
the relationship between the gene and the phenotype,
this approach often misses the minor contributions
of many genes to a phenotype. Image-based assays
that provide high-dimensional read-outs can be used
to classify many genes simultaneously into distinct
functional categories. For example, we have previ-
ously demonstrated that quantitative measurement of
kinase activity can be used in tandem with systematic
large-scale combination RNAi knockdown and pro-
teomics to unravel the regulatory networks of JNK
kinase [12]. Similarly, Bakal et al used large-scale
quantitative morphological signatures to classify hun-
dreds of genes into local groups of genes associated for
speciﬁc aspects of morphology, eg protrusions [20].
The morphology of cells has proved to be a pow-
erful and very sensitive read-out of the involvement
of a gene or genetic relationship in biological pro-
cesses, likely due to the fact that most of these inﬂu-
ence the cytoskeleton [20]. In the future, such assays
can be combined with mutations or over-expressed
genes identiﬁed from deep-sequencing efforts to fur-
ther shine light on complex phenotypes and how they
relate to genotype across cell lines.
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Future biomarkers — network signatures
The principle of multivariate signalling integration
provides a framework for future systems biology-
driven studies because it emphasizes the requirement
for multi-drug/multi-stimulus studies. However, most
current biomarker discovery is not taking this principle
into consideration, which could have potentially dan-
gerous implications. For example, should the phospho-
rylation site on JNK be used as a biomarker, it could
have damaging consequences for the patient, as the
context-dependent or multivariate nature of the regu-
lation of this site would not be immediately apparent
[13,22,23]. It could very well be that in a given patient
or tumour context this site would be anti-apoptotic at a
speciﬁc stage of disease progression. Thus, using this
site as a primary biomarker to determine patient treat-
ment could result in responses to therapeutic agents
opposite to those desired. Therefore, we would sug-
gest that caution be taken in using individual nodes
or modulations (eg a phosphorylation site) outside the
context of a network as indicative or predictive mark-
ers. Instead we encourage that the network models
themselves should be deployed directly as markers.
As we are moving towards multi-dimensional and inte-
grative network models of cell behaviour, we expect
that such models will be useful not just for determin-
ing network structures that can be targeted but also as
predictive markers of disease emergence or progres-
sion [4,22–25]. This will require robust quantitative
network assays to become more widespread and user-
friendly [21]. As mass-spectrometry proteomics con-
tinues to be a challenging technology to master, it is
likely that network models established by quantitative
mass spectrometry in the ﬁrst instance will be easiest
to implement in the clinic as afﬁnity-based microarrays
[4]. However, this will also require the development
of new computational algorithms to analyse such data
[4,8,13].
Networks as drug targets
We previously introduced the concept of network
medicine [18] by describing how protein-signalling
networks, their structure and dynamics are not only
associated with and responsible for driving complex
diseases such as cancers but indeed might also be
powerful drug targets. Recently, two groundbreak-
ing studies have partly validated this suggestion.
In the ﬁrst study, Forest White and Paul Huang
utilized quantitative mass spectrometry to model
EGFR–Met signalling networks and could suggest
potential combination-treatment options for glioblas-
toma [22]. In a more recent paper, Birgit Schorble et al
used computational network models to identify ErbB3
as a therapeutic target, despite it not being an over-
expressed or mutated oncogene in most cancers [23].
In both studies, quantitative network analysis resulted
in some of the fastest-ever clinical trials for new treat-
ments.
The treatment of HIV provides a powerful example
of how targeting the network can be used to control
disease. The reason for the success of highly active
antiretroviral therapy (HAART) is that several antiviral
drugs (typically three or four) are taken in combina-
tion. Side-effects and viral resistance are limited by
following a complex and speciﬁc treatment regime.
Intensive study of the HIV retrovirus life cycle has
led to the identiﬁcation of critical protein networks and
enabled the development of drugs that target these net-
works. HAART has prolonged the life and improved
the quality of life for millions of patients globally. This
therapeutic approach clearly demonstrates the clini-
cal beneﬁt of targeting the network instead of single
molecular targets.
We predict that in future studies, network models
will not be limited to those of signalling molecules
but will also include integrative patterns/signatures
from disease–disease correlations and social net-
works (Figure 3). Recent studies of the relationships
between diseases have suggested that drug side-effects
can be used to associate diseases [26] or that this
can be done through analysis of changes to pro-
tein expression [15,27,28]. In addition to this, we
have recently shown that multiple diseases converge
in a nexus of networks when considering evolution-
ary conserved regulatory networks [16,17]. We pro-
pose that such networks might be crucial multi-node
drug targets [29] in multiple diseases and new tri-
als with combination drugs should be encouraged and
attempted.
Implications for cancer metastasis research
Here, we use metastasis as an example of how network
biology may be applied to tackle a complex and impor-
tant challenge in the treatment of cancer. Metastasis,
the spread of cancer through the body, is a multi-step
process consisting of a series of discrete biological
processes [30]. Each step is regulated by a complex
interplay between cell–cell and cell–matrix interac-
tions and is strongly inﬂuenced by microenvironmental
factors [31]. As tumours grow, space, nutrients and
oxygen become limiting and the cancer cells acquire
the ability to invade into neighbouring tissues and
spread through the body to seek out new terrain [32].
There is a propensity for tumours to seed in partic-
ular organs, which cannot be fully explained by blood
ﬂow. Stephen Paget put forth the ‘seed and soil’ the-
ory in 1889 to explain the patterns of metastases [33].
Paget described tumour cells as ‘seeds’ and the host
environment as the ‘soil’, and proposed that their inter-
action determines metastatic outcome. Hence, without
the correct seed–soil interactions, metastasis to this
site will not take place.
Metastatic progression is thus completely depen-
dent upon cellular context [34]. It is the dynamic
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Figure 3. Integrative network biology-based biomarkers. Through integration of quantitative molecular and behavioural data
collectedfromcellsgrowninconditionsthatmimiccellularcontextsimportanttodisease(cellinteractionsandmicro-environmental
factors), and quantitative data acquired from in vivo models and human patient data, we can deﬁne networks associated with
disease progression and identify network-based biomarkers, thus understanding patient disease in context. The goal of network
medicine and network-based biomarkers is to correlate network dynamics and states to phenotype and patient disease data [18].
The knowledge of social networks might also be useful [45]. Based on integrative network models, potential multi-node signatures
can be deﬁned as markers and/or drug targets. An iterative process can be undertaken to test these networks in tumours and in
combination drug trials. Targeting protein–protein interactions and non-obvious nodes [23,47] in the network will be increasingly
important. Disease networks and social networks can be compared
interactions between tumour cells and their microen-
vironment that determine the metastatic ability of
the tumour. This is clearly demonstrated when one
alters the cellular environment to enable invasion and
metastatic dissemination. For example, hypoxia (low
oxygen) is known to be a potent driving force for
metastatic progression, and there is a plethora of exper-
imental studies to show that oxygen deprivation of
cancer cells enhances their invasive and metastatic
potential [35–38]. These studies have led to the iden-
tiﬁcation of promising anti-metastatic targets, such as
lysyl oxidase (LOX) [37,38]. Cellular context also
determines the response of cancer cells to drug treat-
ment, as recently demonstrated by 3D breast cancer
cell culture studies using Her2-targeting agents [39].
Deﬁning the molecular networks for the metastatic
process presents a major challenge, due to the multi-
tude of interactions and inﬂuencing factors. However,
without an understanding of these networks, we will
never be able to identify effective therapeutic strate-
gies to reduce the number of cancer patient deaths due
to metastases (currently > 90%). In order to tackle the
complex process of metastasis, it is important to iso-
late key steps in progression and focus on deﬁning the
molecular signatures relating to the speciﬁc processes
involved. This can be done through the acquisition of
cell behaviour and molecular data, and has classically
resulted in the generation of cross-comparative lists
that have provided insight into tumour progression.
For example, Kenny et al demonstrated the strength
of performing gene expression and morphology stud-
ies in parallel to investigate breast cancer cell invasion
[40]. In this new era of integrative network biology,
we can now attempt to construct predictive models of
cell behaviour and disease progression through algo-
rithmic integration of systems-level quantitative cell
behaviour and molecular data [4].
The inﬂuence of key interactions can be measured
in vitro using cells by mimicking ‘real-life’ situa-
tions and providing the conditions that create the
context conducive for metastatic progression, eg by
changing the microenvironment to which thehe cells
are exposed or performing cell mixing experiments
to study cell–cell interactions. Studies may also be
performed in vivo using whole organisms, such as
mouse models of cancer. Intravital imaging can be
employed to investigate cell–cell/cell–matrix interac-
tions using differentially labelled tumour/stromal cells
and matrix components [41]. Current technologies
available enable the quantitation of cell behaviour both
in vitro and in vivo. Cell migration, invasion and phe-
notype can be quantiﬁed in a high-throughput manner
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in vitro, using commercially available kits or confocal
microscopy [42], and can be assessed in vivo through
intravital imaging and analysis of pathology [43].
Metastatic growth can be assessed in vivo through
non-invasive imaging of labelled tumour cells (such
as those expressing luciferase using the IVIS system),
ultrasound, PET and CT scanning. In addition, some of
these techniques enable quantiﬁcation of aspects of the
tumour microenvironment, eg tumour oxygenation and
metabolism. PET, CT and MRI scans from human can-
cer patients provide vital clinically relevant data, and
analysis of the pathology of human patient samples
enables the quantitation of certain cellular phenotypes
and behaviour [44].
Quantitative analysis of molecular entities, such as
gene expression studies, deep sequencing and mass
spectrometry proteomics, can be used to understand
the networks associated with metastatic progression.
Molecular, phenotypic and behavioural data can be
collected together in a quantitative systematic man-
ner and integrated computationally to deﬁne the net-
works for the speciﬁc steps in the metastatic process.
These networks can be perturbed using genetic, drug or
other inhibitory methods to conﬁrm predictive ability.
Through the integration of data collected from cells
in vitro, tissue samples from mouse models in vivo
and from human cancer patients, networks can be
deﬁned, ultimately helping us to understand patient
disease in context (Figure 3). These studies will enable
us to understand where promising anti-metastatic tar-
gets, such as LOX, sit in the network and thus how
best to deliver and time therapeutic agents that will
disrupt the network. Without information on the net-
work, single-target agents will likely result in network
compensation and drug resistance, and efﬁcacy in only
a small percentage of patients, as clearly demonstrated
by the majority of clinical trials to date.
Perspectives
In this way, network biology studies will enable us
to address complex biological processes with clini-
cal implications [18,45]. Network biology is maturing
and will revolutionize our understanding of metastasis
and our approach to drug design, ultimately reduc-
ing patient suffering and death. The focus of this new
approach to cancer research is to elucidate at a sys-
tems level how the dynamic behaviour and function
of signalling networks contributes to the process of
cancer progression. To reach this goal, we and others
have shown that computational modelling and quan-
titative measurements must be intimately intertwined
[14]. The reason for this is that network mechanisms
(eg feedback loops and evolutionary conservation)
can only be discovered through integrative studies,
and because these control cell behaviour they are
inherently powerful drug targets [16–18,46,47]. It is
therefore essential that biomarker deﬁnitions progress
from individual nodes to network markers in order to
identify robust, predictive and quantitative markers or
signatures for complex diseases.
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